Discover 10 penny stocks under ₹10 that surged over 20% in a month. Learn about the high-risk, high-reward nature of these investments and see the top performers. Always consult an expert before investing.
Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Nearly 60% of stocks saw weaker returns in 2025 vs 2024. Will 2026 bring another flip? Experts reveal the key factors for sustained outperformance. Read more.
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
India plans a major pharma licensing overhaul with a separate wholesale licence for bulk drugs and APIs to improve traceability and safety. This move follows global scrutiny over contaminated cough syrups and aims to regulate a $50-billion market.
Aurobindo Pharma strengthens its domestic formulations market with a ₹325 crore acquisition of Khandelwal Laboratories' non-oncology business. The deal includes 23 established brands and boosts presence in pain & anti-infective segments. Read more.
Wall Street's major indexes fell slightly on the last trading day of 2025 but are set for strong double-digit yearly gains, fueled by AI stocks. Nike and Vanda Pharma saw notable moves.
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
Orange Biotech Private Limited unveils a nationwide PCD pharma franchise with high-profit margins, monopoly rights, and extensive product portfolio for entrepreneurs. Start your own pharma business today!
Aurobindo Pharma's Dutch arm buys 20% more in China's Luoxin Aurovitas for $5M, aiming for 100% ownership by 2029 to scale up inhalation product manufacturing. Read the full strategic move.
JioHotstar's new series 'Pharma' ignites public debate on drug pricing, ethics, and accessibility in India's healthcare system. Read the full analysis.
As 2025 ends, markets turn cautious. Choice Broking's Hitesh Tailor picks 4 stocks with strong technical setups for 2026. Read for targets & analysis.
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
UST and IIT Madras Incubation Cell sign MoU to accelerate healthcare startups. 'Pitch to Win: Pharma 4.0' challenge sees 90+ entries. Winners get funding up to Rs 45 lakh. Read more.
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Sun Pharmaceutical shares fell over 3% after a US FDA inspection at its Baska plant. The inspection concluded with 3 observations. Get the full details on the market impact and company's response.
Odisha CM Mohan Majhi positions state as top pharma & medical devices investment destination. New policy & parks attract Rs 7,043 crore proposals, 45 MoUs signed. Read more.
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
India's winter wedding season with 45-50 lakh weddings between November-December 2025 creates investment opportunities in jewellery, hospitality and travel stocks. Expert picks revealed.
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.